A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from: J.P. The offering may be made only by means of a prospectus supplement and accompanying prospectus. The offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by RAPT with the Securities and Exchange Commission (SEC), which was declared effective by the SEC on November 16, 2020. Cantor is acting as book-running manager for the proposed offering. Morgan, SVB Leerink and Piper Sandler are acting as joint lead book-running managers for the proposed offering. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares of common stock are being offered by RAPT. In addition, RAPT expects the underwriters to be granted a 30-day option to purchase up to an additional $18.75 million of its common stock on the same terms and conditions.

(Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc.

Rapt with attention